阿斯利康15亿美元引进中国肺癌药
2026-07-14 07:12:23
据彭博社报道，阿斯利康将向中国迪哲江苏制药支付6亿美元预付款，以获得一款肺癌药物的全球权利；该交易总额为15亿美元，为其产品线增加一款接近商业化的治疗方案。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
股票市场 | 路透：Shein拟在香港上市前换帅，许仰天将接任主席Next article：
会财局：近月未见大规模IPO审计质量参差情况
